N-methyl-N-dithiocarboxyglucamine

N-methyl-N-dithiocarboxyglucamine (MDCG), also referred to as NMG-DTC, primarily functions as a highly effective therapeutic chelating agent designed for heavy metal detoxification and the mitigation of chemotherapy-induced side effects. Its structural design combines a heavy-metal-binding dithiocarbamate group with a highly water-soluble glucamine backbone. [1, 2, 3]

• Cadmium Mobilization and Excretion: MDCG serves as one of the most effective agents for treating acute and chronic cadmium (Cd) intoxication. It directly attacks and strips heavy metals bound to intracellular proteins like metallothionein. Once complexed with MDCG, the cadmium is safely mobilized and expelled from the body—primarily through biliary secretion into the feces. [1, 2, 3, 4]
• Organ Protection (Liver and Kidneys): It significantly lowers the heavy metal burden in the organs most vulnerable to toxicity, specifically the liver and kidneys. Unlike older therapeutic chelators, it mobilizes heavy metals out of the body without causing dangerous redistributions into sensitive structures like the brain, testes, or heart. [1, 2]
• Reduction of Cisplatin Nephrotoxicity: In oncological research, MDCG acts as a chemoprotective counteragent. When administered in a strategic window alongside the chemotherapy drug cisplatin, it prevents severe kidney damage—significantly curbing spikes in blood urea nitrogen (BUN) and serum creatinine. Crucially, it achieves this renal protection without interfering with cisplatin's primary anti-tumor efficacy. [1]
• Broad Heavy Metal Detoxification Research: Beyond cadmium, it is widely utilized in preclinical toxicological models to study the chelation and clearance kinetics of other hazardous elements like lead (Pb) and arsenic (As). [1, 2]
•